An Expanded Phase I Study of Pazopanib and Everolimus in Patients With Advanced Solid Tumors and Previously Treated Advanced Urothelial Cancer
Phase of Trial: Phase I
Latest Information Update: 06 Oct 2017
At a glance
- Drugs Everolimus (Primary) ; Pazopanib (Primary)
- Indications Renal cancer; Solid tumours
- Focus Adverse reactions; Therapeutic Use
- 03 Oct 2017 Status changed from active, no longer recruiting to completed.
- 01 Aug 2017 Planned End Date changed from 1 Jun 2017 to 1 Aug 2017.
- 10 Jun 2017 Biomarkers information updated